Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose(TM) Technology Entitled "Low Glycemic Sugar Composition."

Stock Information for Impact BioMedical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Impact BioMedical Inc.

DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger
DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
Sentinel Brokers Company, Inc., a Subsidiary of DSS, Inc., Receives FINRA Approval to Act as Underwriter and Selling Group Member for Corporate Securities Offerings
DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
DSS, Inc. Issues Letter to Shareholders
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value
AmericaFirst Funds Trust Announces Changes to Board of Trustees
DSS, Inc. Names Jason Grady as Interim Chief Executive Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.